Why Alzheimer’s Risk Looks Different in Women

Genetics provide information. What we do with that information is where prevention begins.

Nearly two thirds of Americans living with Alzheimer’s disease are women. For years, that gap was explained away by longevity alone. Women live longer than men, so of course they would accumulate more age related disease. The more I read the research, though, the more I’m convinced that answer is incomplete. The female brain appears to move through a unique convergence of genetic, hormonal, metabolic, and inflammatory changes that shape Alzheimer’s risk in ways we are only beginning to understand.

At the center of this conversation sits a small but important gene called APOE. Knowing your APOE status does not predict your future. It does offer insight into how risk develops and where prevention efforts may have the greatest impact – and for my female patients in perimenopause and beyond, that insight can be genuinely useful.

What APOE Actually Does

APOE, or Apolipoprotein E, is involved in cholesterol transport, brain repair, inflammation regulation, amyloid clearance, and overall neuronal health. Every person inherits two copies of the APOE gene, one from each parent, and those copies can be combinations of three primary variants: APOE2, APOE3, and APOE4. The pairing you inherit is your APOE genotype, and it influences your relative risk profile – but the three variants do not behave the same way.

APOE2, APOE3, and APOE4

• APOE2 appears to be the most protective variant. Carriers often show lower amyloid accumulation, greater neuronal resilience, and a lower overall risk of Alzheimer’s disease. Protection is not immunity, but the profile tends to be favorable.
• APOE3 is considered neutral and serves as the baseline for comparison. Roughly sixty percent of people carry APOE3/3, making it the most common genotype worldwide.
• APOE4 is different. Carrying one APOE4 allele may raise Alzheimer’s risk two to four fold, and APOE4/4 carries the highest common genetic risk profile for late onset Alzheimer’s disease, with substantially higher risk than APOE3/3.

I want to be very clear about one thing: APOE4 is not a diagnosis. Many people who carry it never develop dementia. Genetics influence risk. They do not determine destiny.

Why APOE4 Hits Women Differently

One of the most interesting threads in Alzheimer’s research is the interaction between APOE4 and menopause. Estrogen is not just a reproductive hormone. In the brain, it supports glucose metabolism, mitochondrial function, synaptic plasticity, neuroprotection, and anti inflammatory signaling. When estrogen declines sharply through the menopausal transition, the brain has to renegotiate how it fuels and protects itself. Some researchers describe this period as a brain energy transition, and I think that framing is spot on.

During that transition, several changes can occur at once: brain glucose metabolism decreases, inflammatory signaling increases, amyloid accumulation may accelerate, and APOE4 related vulnerabilities become more apparent. That overlap may help explain why women carrying APOE4 appear particularly susceptible to cognitive decline compared with men carrying the same genotype. It is not simply that women live longer. Their brains are navigating a hormonal shift that men do not experience in the same way.

The Hormone Conversation Is Evolving

The relationship between hormone replacement therapy and Alzheimer’s prevention is one of the most actively debated topics in women’s health, and for good reason. Estrogen influences memory formation, cerebral blood flow, mitochondrial energy production, synaptic growth, and amyloid regulation. Brain imaging studies have documented reductions in cerebral glucose metabolism during the menopausal transition, and those patterns can resemble changes seen in early Alzheimer’s disease years before symptoms appear.

So the question in my office is rarely whether hormones matter for the brain. The more honest question is when intervention makes the most sense.

The Critical Window Hypothesis

Current evidence suggests timing plays a significant role. Women who begin hormone therapy near menopause onset, often within ten years of menopause, may experience more favorable neurological outcomes than women who start much later. Earlier intervention may help support brain metabolism, cognitive resilience, and vascular health. The data are not uniform, and individualized decision making remains essential, but the conversation is shifting away from blanket recommendations and toward personalized risk assessment. That is a good thing.

Beyond Estrogen: Progesterone and Testosterone

Brain health does not hinge on estrogen alone. Progesterone contributes to neuroprotection, stress resilience, sleep quality, and GABA regulation. Sleep matters enormously here, because deep sleep is when the brain uses the glymphatic system to clear amyloid proteins. If progesterone loss is disrupting your sleep, that is not a cosmetic problem. It is a brain health problem.

Testosterone also declines with age and influences executive function, motivation, mood, lean muscle mass, and metabolic health. Because metabolic dysfunction and insulin resistance are closely linked to dementia risk, maintaining overall hormonal balance has implications that stretch well beyond symptom relief.

A New Frontier: GLP-1 Medications

Another emerging area involves GLP-1 receptor agonists such as semaglutide, tirzepatide, and liraglutide. Originally developed for diabetes, these medications appear to influence several pathways involved in neurodegeneration. Researchers are particularly interested in their potential effects on:

• Insulin sensitivity
• Glucose regulation
• Neuroinflammation
• Mitochondrial function
• Cardiovascular health

Because insulin resistance is strongly associated with cognitive decline, improving metabolic function may prove to be an important preventive strategy. Large Alzheimer’s prevention trials involving semaglutide are currently underway, and their results may reshape how we approach cognitive health in the coming years.

Lifestyle Still Carries the Most Weight

Here is the piece I most want women to hold onto: risk remains highly modifiable. Even among APOE4 carriers, lifestyle appears to exert a powerful influence on long term outcomes. The areas that consistently show up in the research are the same ones I return to with patients every week.

• Regular aerobic exercise
• Resistance training and muscle preservation
• Sleep optimization
• Blood sugar control
• Inflammation reduction
• Cardiovascular risk management
• Social engagement and lifelong learning

These interventions influence many of the same pathways implicated in Alzheimer’s disease itself – insulin sensitivity, inflammation, mitochondrial function, vascular health, and brain resilience. None of them require a prescription. All of them compound over time.

The Bigger Picture

You cannot change your APOE genotype. You can influence how that genetic risk is expressed over time. For women, the intersection of APOE4, menopause, estrogen decline, metabolic health, inflammation, and cardiovascular risk creates a real opportunity for earlier, more personalized prevention.

The future of Alzheimer’s care may not begin when memory loss appears. It may begin decades earlier, by identifying risk, understanding physiology, and acting before disease develops. Genetics provide information. What we do with that information is where prevention actually begins.